Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SCI Interim / Quarterly Report 2015

Dec 3, 2015

52383_rns_2015-12-03_b6078a86-58b8-45e2-96e4-76651c140461.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

員工數Employee:216 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣750佰萬元(NTD 750mn) 營業項目Business: 原料藥API(55.59%) 中間體Intermediate(38.43%) 特用化學品 Custom-made chemicals(5.98%)

公司概況Outline

Y2014 Y2015

洲Europe
42.65% 36.13%

洲America
21.70% 32.09%

洲Asia
18.18% 19.60%

內Taiwan
16.63% 9.22%
他 others
0.84% 2.96%
計Total
100.00% 100.00%

Unit: K NTD

2015 Q1 2015 Q2 2015 Q3 2015.Oct
營收Sales 443,065 579,644 438,507 198,030
營業成本COGS (273,443) (360,661) (292,627) (119,539)
毛利Gross Profit 169,622 218,983 145,880 78,491
毛利率 GP Ratio 38.3% 37.8% 33.3% 39.6%
營業費用Operating Expenses (53,885) (64,179) (50,272) (24,361)
營業利益Operating Income 115,737 154,804 95,608 54,130
營業外損益Non-Operating In/Ex(2,070) (5,449) 19,441 (3,157)
稅前淨利 Net Profit before Tax 113,667 149,355 115,049 50,973
所得稅Income Tax (20,849) (24,605) (19,847)
本期淨利Net Profit after Tax 92,818 124,750 95,202

產品組合-Products

Y2012 % Y2013 % Y2014 %
V.A. 18.66% PGA 18.31% PGA 17.49%
PGA 16.61% Di-VaNa 16.92% Di-VANa 10.09%
Di-VaNa 15.97% S20/38 8.39% LPF.Na 8.74%
PPON 7.88% V.A. 8.23% S20/38 8.25%
Pent-2 4.78% LPF.Na 6.58% V.A. 8.15%
5-HMT 4.33% PPON 6.53% DBS 4.60%
M85 3.89% 5-HMT 4.51% 5-HMT 4.12%
DBS 2.73% PEB.Na 3.98% NaVA 3.65%
M115 2.59% NaVa 3.34% Pent-2 3.64%
M74 2.18% DBS 2.63% T115 3.33%
Total 79.62% Total 79.42% Total 72.06%
No. Product % 2015 Sales (NT\$)
1 HOCLQ Sulfate 22.15% 367,526,433
2 PGA 16.02% 265,876,797
3 V.A. 11.43% 189,656,214
4 LPF.Na 8.14% 135,143,000
5 Di-VaNa 5.74% 95,202,846
6 S2038 4.36% 72,402,057
7 DBS 3.26% 54,030,549
8 5-HMT 2.82% 46,770,544
9 Pent-2 2.50% 41,520,945
10 NaVA 2.10% 34,866,423

  • Hydroxychloroquine sulfate

  • 2015sales: 367M

風濕性關節炎藥物 For rheumatoid arthritis 8個客戶 8 customers

Pyrogallolaldehyde ( PGA) - Benserazide

治療帕金森氏症之中間體 Intermediate for Parkinson's Disease

2個客戶 2 customer

2015 sales: 266M

Anti-inflammatory (Loxoprofen sodium)

日本市場200-300公噸 Japan market:200-300MT 2015 sales: 135M

S20/38

臨床藥物 Medication in clinical trial 2015 sales: 72M

Valproic Acid (VA)

20個客戶 20 customers 2015 sales: 190M

產品介紹Product

Divalproex Sodium (Di-Va)

學名藥於2009推出 Generic came out in 2009 12個客戶 12 customers 2015 sales: 95M

產品介紹Product

Pentobarbital Sodium (鎮定安眠用, calmative)

2015 sales:29M

Pent-2

Antidepressant (Duloxetine) 2013年底專利到期 Patent expired in the end of 2013 2014 sales: 12 M 2015 sales: 32M

Antidepressant (S-MMAA) Duloxetine之中間體 intermediate of Duloxetine 2014 sales: 27 M 2015 sales: 22 M

Sodium Valproate (NaVA)

5-HMT – Ritonavir,Lopinavir

24 客戶 24 customers 2015 sales: 35M

愛滋病藥物中間體 For AIDS treatment 2015 sales: 47M

GMP Status(GMP現況)

API CGMP
Certified
(TFDA)
CEP
(EDQM)
DMF
(USA)
MF
(Japan)
DMF
(Canada)
Valproic Acid (*) (#) 2003 2004 2003 2008 2008
Allopurinol 2004 2003 2011
Sodium
Valproate
2004 2006
Divalproex
Sodium
(**)(#)
2005 2005 2010
Bisoprolol
Fumarate
2006
Pentobarbital
Sodium
2009 2
011
Propafenone
Hydrochloride
2010 2012 2010 2012 2012
Methylphenidate
HCl
2
011
2014
Duloxetine
Hydrochloride
2012 2014 2010/2011
Thiopental 2012
Loxoprofen
Sodium
Hydrate
2012 2011
Articaine
Hydrochloride
2013 2014 2014
Hydroxychloroquine
Sulfate(#)
2014 2014 2014
Clindamycin
Palmitate
HCl
2011
Cyclophosphamide 2014 2012
Brinzolamide 2015 2015
Probucol 2015 2004

(*)(**) FDA inspection: Nov. 2005 / April 2012, (*) EDQM inspection: Nov. 2010, (#) FDA inspection: Dec. 2014.

敬 請 指 教